Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.

C Araujo, John; Mathew, Paul; J Armstrong, Andrew; L Braud, Edward; Posadas, Edwin; Lonberg, Mathew; E Gallick, Gary; C Trudel, Géralyn; Paliwal, Prashni; Agrawal, Shruti; J Logothetis, Christopher

doi:10.1002/cncr.26204

Public

Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.

Shared by NobleBlocks on Jan 1, 2012 • 12:00 AM UTC

Authors:

John C Araujo

Paul Mathew

Andrew J Armstrong

Abstract

BACKGROUND: To determine the potential efficacy of targeting both the tumor and bone microenvironment in patients with castration-resistant prostate cancer (PC), the authors conducted a phase 1-2 trial combining docetaxel with dasatinib, an oral SRC inhibitor. METHODS: In phase 1, 16 men received da...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!